BGI
FHTX icon

B Group Inc’s Foghorn Therapeutics FHTX Stock Holding History

B Group Inc’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$488K Buy
+102,000
New +$560K 0.36% 18

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

B Group Inc's FHTX Position: Q1 2026 in Review

B Group Inc opened a new position in Foghorn Therapeutics (FHTX) in Q1 2026: 102,000 shares worth $488K. The stake represents 0.36% of the portfolio and ranks #18 among its holdings.

105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

  • B Group Inc held 102,000 shares of Foghorn Therapeutics worth $488K as of Q1 2026.
  • Foghorn Therapeutics was a new B Group Inc position in Q1 2026.
  • Foghorn Therapeutics made up 0.36% of B Group Inc's portfolio in Q1 2026, its #18 holding.
  • 105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on B Group Inc's 13F filing for Q1 2026, filed 15 May 2026.